TOKIO rationale and protocol: A phase II study to evaluate the activity and safety of third-line tyrosine kinase inhibitor after 2 tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma

Elena Verzoni, Paolo Grassi, Rosanna Montone, Giulia Galli, Andrea Necchi, Giuseppe Procopio

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'TOKIO rationale and protocol: A phase II study to evaluate the activity and safety of third-line tyrosine kinase inhibitor after 2 tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences